Clean Science & Technology Limited has submitted its quarterly confirmation certificate to stock exchanges, reporting zero dematerialization activity for the quarter ended March 31, 2026. The filing fulfills mandatory regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018.

Regulatory Compliance Filing

The company filed the confirmation certificate with both BSE Limited and National Stock Exchange of India Limited on April 7, 2026. This submission is required under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.

Registrar Confirmation

MUFG Intime India Private Limited, formerly Link Intime India Private Limited, serves as the company's registrar and share transfer agent. The registrar confirmed in its certificate dated April 6, 2026, that no securities were received for dematerialization during the specified quarter.

The confirmation was signed by Ashok Shetty, Vice President – Corporate Registry at MUFG Intime India Private Limited. MUFG Intime India operates under CIN U67190MH1999PTC118368 and holds SEBI registration number INR000004058.

Corporate Compliance

Ruchita Vij, Company Secretary and Compliance Officer of Clean Science and Technology Limited, digitally signed the submission on April 7, 2026. The filing demonstrates the company's adherence to quarterly reporting obligations mandated by securities market regulations.

This routine compliance filing indicates that no shareholders requested conversion of physical share certificates to electronic form during the quarter ended March 31, 2026. Such quarterly confirmations are standard regulatory requirements for all listed companies to maintain transparency in their shareholding patterns and dematerialization activities.

Clean science & technology Limited has announced key managerial personnel appointments effective from April 1, 2026, following approvals from shareholders through different governance processes. The specialty chemicals company communicated these leadership changes to stock exchanges under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Leadership Appointments Overview

The company has made three significant appointments to strengthen its executive leadership team:

Approval Process and Timeline

The appointments received shareholder approval through established corporate governance processes. Mr. Krishnakumar Boob's re-appointment as Whole-Time Director was approved during the Annual General Meeting held on September 11, 2025, securing his position for a five-year term from April 1, 2026 to March 31, 2031.

The appointments of Mr. Ashok Boob and Mr. Siddhartha Sikchi were approved through Postal Ballot dated December 16, 2025. Mr. Ashok Boob will serve as Whole Time Director – Executive Vice Chairman from April 1, 2026 up to July 27, 2027, while Mr. Siddhartha Sikchi's tenure as Managing Director extends from April 1, 2026 to March 31, 2031.

Executive Profiles and Experience

All three appointees bring substantial industry experience and have been instrumental in the company's development. Mr. Krishnakumar Boob holds a bachelor's degree in pharmacy from the University of Bombay and brings around three decades of chemical industry experience. He previously worked as a director at Mangalam Drugs and Organics Limited and currently holds 2,12,000 equity shares representing 0.20% stake in the company.

Mr. Ashok Boob, who holds a bachelor's degree in chemical engineering from the Institute of Chemical Technology, Mumbai, brings close to 50 years of chemical industry experience. As a career-technocrat and promoter director, he has been instrumental in the company's expansion since inception, holding 36,71,510 equity shares constituting 3.45% of the company.

Mr. Siddhartha Sikchi holds a Master's degree in Science in Organic Chemistry from University of Manitoba, Canada, and a Bachelor's degree in Chemical Technology from Institute of Chemical Technology, Mumbai. With around two decades of specialty chemical industry experience, he holds 57,50,425 equity shares representing 5.41% of the company.

Corporate Governance Roles

The appointees serve on various board committees, enhancing corporate governance structure:

Regulatory Compliance

The company confirmed that all three appointees meet regulatory requirements and are not debarred from holding director positions by SEBI or any other authority, as required under BSE and NSE circulars dated June 20, 2018. The appointments reflect the company's commitment to maintaining experienced leadership while ensuring compliance with corporate governance standards.